ACROBiosystems target antigens for CAR-T therapy development

Chimeric antigen receptor T (CAR-T) cell therapy is a groundbreaking approach in combating various cancers. The principle lies in harnessing the patient’s T cells and genetically modifying them to express a chimeric antigen receptor designed to recognise specific tumour-associated antigens (TAAs). Upon reintroduction into the patient’s system, these CAR-expressing T-cells effectively target and eliminate tumour cells expressing the TAAs.

Evaluating CAR expression is an essential step in CAR-T cell production. This is often done by flow cytometry, using protein L, anti-Fab antibodies or target antigens as detection methods. Target antigens are a particularly optimal choice due to their high specificity and minimal background staining.

ACROBiosystems has developed an extensive collection of recombinant proteins to support CAR-T therapy development. The company’s growing list of proteins includes many fluorescent-labelled target antigens and pre-biotinylated proteins that are suitable for evaluating CAR expression.

Fluorescence-labelled antigens feature pre-labelled target antigens with a fluorescent dye, simplifying detection and streamlining processing time by eliminating the need for secondary antibodies, thus reducing nonspecific reactions. On the other hand, Biotin-streptavidin-labelled proteins utilise antigens pre-labelled with biotin, detected via streptavidin, resulting in a biotin-avidin complex. Moreover, the fluorochrome-labelled streptavidin enables high-affinity binding to biotinylated proteins, enhancing signal detection for heightened sensitivity and specificity.

In addition, ACROBiosystems supplies difficult-to-express proteins such as BCMA, CD19, ROR1 and EGFRVIII.